Lexicon Pharmaceuticals

Infobox_Company
company_name = Lexicon Pharmaceuticals
company_
company_type = Public (nasdaq|LXRX)
company_slogan = Discovering and Developing Breakthrough Treatments For Human Disease
foundation = The Woodlands, TX, 1995
location = The Woodlands, flagicon|USA USA
key_people = [http://www.lexpharma.com/about-us/management Arthur T. Sands] , CEO Alan J. Main, VP

num_employees = 450 (2008)
industry = Health Care
homepage = [http://www.lexpharma.com/ www.lexpharma.com]

Lexicon Pharmaceuticals (Nasdaq [http://finance.yahoo.com/q?s=LXRX LXRX] ) is a medium sized biopharmaceuticals company founded in The Woodlands, Texas that started operation in 1995 during the biotech bubble under the name Lexicon Genetics. Their early business emphasized the use of their patented mouse knockout technology and extensive "in vivo" screening to identify potential therapeutic targets [ [http://www.lexgen.com/pdf/nrd987_fs.pdf| Zambrowicz, BP; Sands, AT (2003). Knockouts model the 100 best-selling drugs--will they model the next 100? Nature Reviews of Drug Discovery. 2 (1): 38 - 51] ] . In June, 2003 Lexicon Genetics purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey [ [http://www.secinfo.com/dsvRu.4F9W3.c.htm United States Securities and Exchange Commission] ] , and in 2007, they changed their name to Lexicon Pharmaceuticals to reflect their renewed focus on drug development.

References